Company Encyclopedia
View More
name
Arcutis Biotherapeutics
ARQT.US
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc.
1.946 T
ARQT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking75/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-28.17%E
    • Profit Margin-13.94%D
    • Gross Margin91.25%A
  • Growth ScoreA
    • Revenue YoY129.21%A
    • Net Profit YoY77.33%A
    • Total Assets YoY-15.18%E
    • Net Assets YoY0.91%C
  • Cash ScoreC
    • Cash Flow Margin-717.28%E
    • OCF YoY129.21%A
  • Operating ScoreB
    • Turnover0.79B
  • Debt ScoreD
    • Gearing Ratio57.39%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dir Welgus Sells 10,000 ($302.1K) Of Arcutis Biotherapeutics Inc [ARQT]

    Welgus Howard G Director of Arcutis Biotherapeutics Inc [ARQT] filed a Form 4 on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/1/25TransactionPlanned Sale(1) Shares10,000Price$30.21Value$302,133Ending Holdings: 79,744 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    ARQT
    +4.01%
    Reuters·
    US
    ARQT
    +4.01%

    Director Howard G. Welgus Reports Disposal of Arcutis Biotherapeutics Inc. Common Shares

    Howard G. Welgus, Director at Arcutis Biotherapeutics Inc., reported the disposal of common shares of the company. This announcement was made via EDGAR by the U.S. Securities and Exchange Commission on December 03, 2025.

    Reuters·
    US
    ARQT
    +4.01%
    Reuters·
    US
    ARQT
    +4.01%

    American Century Companies Inc. Purchases 71,815 Shares of Arcutis Biotherapeutics, Inc. $ARQT

    American Century Companies Inc. increased its stake in Arcutis Biotherapeutics by 4.3% in Q2, owning 1.44% of the company. Insider transactions included significant stock sales by Masaru Matsuda and Sue-Jean Lin. Analysts have given Arcutis a moderate buy rating, with a consensus target price of $29.00. The company's stock opened at $30.37, with a market cap of $3.72 billion. Recent earnings exceeded expectations, with $99.22 million in revenue.

    Market Beat·
    US
    ARQT
    +4.01%
    Market Beat·
    US
    ARQT
    +4.01%

    Mizuho Securities Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)

    Mizuho Securities, through analyst Uy Ear, reaffirmed a Buy rating for Arcutis Biotherapeutics with a price target of $37.00. The analyst covers the Healthcare sector and has an average return of -0.3% with a 38.24% success rate. The consensus among analysts is a Strong Buy rating with a $29.50 average price target for Arcutis Biotherapeutics.

    Tip Ranks·
    US
    ARQT
    +4.01%
    Tip Ranks·
    US
    ARQT
    +4.01%

    Dir Lin Sells 25,272 ($778K) Of Arcutis Biotherapeutics Inc [ARQT]

    Lin Sue-Jean, Director of Arcutis Biotherapeutics Inc [ARQT], sold 25,272 shares worth $778K on November 24, 2025. The shares were sold at $30.78 each. Lin also exercised 25,272 shares at $8.31 each. Ending holdings are 26,735 shares. The transaction was disclosed in a Form 4 filed with the SEC.

    Reuters·
    US
    ARQT
    +4.01%
    Reuters·
    US
    ARQT
    +4.01%
    © 2025 Longbridge｜Disclaimer